Rein Therapeutics Inc. (RNTX)

Market Cap	58.50M
Revenue (ttm)	n/a
Net Income (ttm)	-29.24M
Shares Out	21.67M
EPS (ttm)	-2.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	118,601
Open	2.960
Previous Close	2.680
Day's Range	2.540 - 2.960
52-Week Range	1.610 - 7.420
Beta	2.23
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 14, 2025

About RNTX

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes pre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: RNTX
• Website: https://www.reintx.com